The purpose of the study is to evaluate the efficacy and safety of rh-prouk as pharmacoinvasive therapy on those ST Elevated Myocardial Infarctions patients, it is designed as a multicenter, active controlled, single blinded study. The primary endpoint is to assess the coronary recanalization 90 minutes after thrombolysis. The secondary endpoint is to evaluate the mortality rate at day 30.
The purpose of the study is to evaluate the efficacy and safety of rh-prouk as pharmacoinvasive therapy on those ST Elevated Myocardial Infarctions patients, it is designed as a multicenter, active controlled, single blinded study. The primary endpoint is to assess percentage of patients achieve the coronary recanalization 90 minutes after thrombolysis. The secondary endpoint is to evaluate the mortality rate at day 30.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
450
rh-prouk will be administrated within 60 minutes after the patients eligibility confirmed
Shenyang Northern Hospital
Shenyang, Liaoning, China
RECRUITINGTo compare the percentage of STEMI patients achieving the recanalization of Coronary between the two arms
Time frame: 90 minutes after administrative of active/comparator
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.